Liver Elastography (FibroScan)

Understand

Overview

Liver elastography, most often performed using the transient elastography technique under the commercial name FibroScan, is a non-invasive test assessing the mechanical stiffness of liver tissue as an indirect indicator of the degree of its fibrosis. As chronic liver disease progresses, normal, elastic tissue is gradually replaced by stiffer connective tissue, which changes the organ's physical properties in a way that can be measured without needing to take a tissue sample for histopathological examination.

The clinical significance of this test stems from the fact that for decades, biopsy was the only method for assessing the extent of liver fibrosis — an invasive procedure carrying a risk of complications, pain, and sampling error resulting from assessing a small, point sample of a large organ. Elastography provides a quantitative, continuous numerical value expressed in kilopascals (kPa), correlated with the degree of fibrosis on a scale from F0 (no fibrosis) to F4 (cirrhosis), without any of these limitations — it assesses a much larger volume of tissue than a typical biopsy sample, can be performed in an office setting in a few minutes, and can be repeated any number of times without the risk of accumulating a harmful agent.

The test is ordered primarily in the context of non-alcoholic fatty liver disease (NAFLD, now increasingly referred to as MASLD), where the key clinical question is whether a patient with fatty liver has already developed significant fibrosis requiring more intensive monitoring. A second large group of indications is chronic viral hepatitis B and C, where elastography serves both for the initial assessment of disease severity and for monitoring fibrosis regression after successful antiviral treatment. A third group is alcohol-related liver disease, and a fourth is screening for advanced fibrosis in people with diabetes or obesity, in whom the risk of undetected, advanced liver disease is elevated despite the absence of typical symptoms.

On the practical side, the test is fully non-invasive and painless. The patient lies on their back with their right arm raised behind their head, which widens the intercostal spaces, and the operator applies the device's probe to the skin over the lower ribs on the right side, above the right lobe of the liver. For reliable interpretation, at least ten valid measurements are recommended, from which the device calculates a median value — the whole test usually takes five to ten minutes, and the result is available immediately after it's finished, without the wait typical of laboratory or histopathological tests. A key element of preparation is fasting for at least two to three hours before the test, since eating significantly increases blood flow in the portal vein, which artificially raises the measured liver stiffness.

Several misunderstandings have grown up around elastography that are worth dispelling. Some patients equate it with an ordinary abdominal ultrasound — in reality, it's a distinct technique measuring the mechanical stiffness of tissue rather than its anatomical structure, though both tests are sometimes performed with the same device or during the same visit and complement each other. Another common misconception is treating the result as a pure, exclusive reflection of fibrosis — tissue stiffness is also raised by acute inflammation, passive congestion in heart failure, or bile stasis, which is why the result always requires interpretation in clinical context rather than being read in isolation.

Modern transient elastography devices simultaneously record, alongside the stiffness measurement, the CAP parameter (controlled attenuation parameter), assessing the degree to which fatty tissue attenuates the ultrasound wave — thanks to this, one, several-minute test provides two independent pieces of information: the approximate degree of fibrosis and the degree of liver steatosis, without needing two separate procedures.

Liver elastography has revolutionized non-invasive hepatology diagnostics, allowing a significant proportion of patients to avoid a liver biopsy or substantially limiting the number of biopsies performed to genuinely ambiguous cases. It doesn't, however, replace biopsy entirely — where the result is borderline, several liver diseases are suspected to coexist, or an assessment of inflammatory activity unavailable from a stiffness measurement alone is needed, biopsy remains an irreplaceable diagnostic tool.